BNTX vs. DHR: BioNTech vs. Danaher Stock Comparison
How do BioNTech (BNTX) and Danaher (DHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioNTech (BNTX) and Danaher (DHR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while DHR is classified in Life Sciences Tools & Services.
Danaher (DHR) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BNTX | DHR |
|---|---|---|
| Name | BioNTech SE American Depositary Share | Danaher Corp. |
| Country/Region | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 21.70 billion USD | 161.86 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | October 10, 2019 | December 29, 1978 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Total Return (1Y) | -14.78% | 11.88% |
| Total Return (3Y, Annualized) | -3.99% | 6.67% |
| Total Return (5Y, Annualized) | -17.02% | -2.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Volatility (1Y, Annualized) | 47.44% | 30.61% |
| Beta (5Y) | 1.30 | 0.76 |
| Max Drawdown (5Y) | -78.10% | -43.31% |
| Avg. Volume (3M) | 1.21M | 3.94M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Sharpe Ratio (1Y) | -0.40 | 0.25 |
| Sortino Ratio (1Y) | -0.59 | 0.35 |
Profitability
ROE (TTM)
BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Danaher (DHR) reports 8.19%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.14%
- Max
- 109.18%
- Q3
- 6.23%
- BNTX
- -8.14%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Danaher (DHR) reports 16.91%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.87%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BNTX
- -60.87%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BioNTech (BNTX) at 30.28% and Danaher (DHR) at 21.13% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.28%
- Max
- 83.12%
- BNTX
- 30.28%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BNTX | DHR |
|---|---|---|
| ROE (TTM) | -8.14% | 8.19% |
| ROA (TTM) | -4.04% | 4.06% |
| Net Margin (TTM) | -60.87% | 16.91% |
| Operating Margin (TTM) | 30.28% | 21.13% |
| Gross Margin (TTM) | 76.73% | 59.36% |
Growth
Revenue Growth
Both BioNTech (BNTX) at 4.32% and Danaher (DHR) at 2.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Danaher (DHR) reports EPS growth of -4.54%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.
Growth Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Revenue Growth (YoY) | 4.32% | 2.90% |
| Revenue Growth (3Y CAGR) | -45.06% | -2.67% |
| EPS Growth (YoY) | -- | -4.54% |
| EPS Growth (3Y CAGR) | -- | -19.44% |
Financial Strength
Current Ratio (MRQ)
BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Danaher (DHR) at 1.63 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for DHR.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.55
- Max
- 25.13
- Q3
- 12.13
- BNTX
- 8.55
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
Debt / Equity (MRQ)
BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Danaher (DHR) at 0.52 runs a more typical debt-to-equity mix.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- BNTX
- 0.02
- Min
- 0.00
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Current Ratio (MRQ) | 8.55 | 1.63 |
| Debt / Equity (MRQ) | 0.02 | 0.52 |
| Net Debt / EBITDA | -- | 2.68 |
Dividends
Dividend Yield (TTM)
BioNTech (BNTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
BioNTech (BNTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BNTX | DHR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.67% |
| Dividend Payout Ratio (TTM) | 0.00% | 25.17% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Danaher (DHR) trades at 38.12 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BNTX
- --
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both BioNTech (BNTX) at 8.96 and Danaher (DHR) at 6.32 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.96
- Max
- 58.18
- Q3
- 25.77
- BNTX
- 8.96
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Danaher (DHR) at 3.02 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BNTX
- 1.09
- Min
- -5.59
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BNTX | DHR |
|---|---|---|
| P/E Ratio (TTM) | -- | 38.12 |
| P/S Ratio (TTM) | 8.96 | 6.32 |
| P/B Ratio (MRQ) | 1.09 | 3.02 |
| Free Cash Flow Yield (TTM) | -7.34% | 2.93% |